GUIDELINES RAPID REVIEW II / EXAMEN RAPIDE DES LIGNES DIRECTRICES II

Disclosure(s):

Jonathan Howlett: AstraZeneca: Consultant/Advisory Board (Terminated, May 30, 2023), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, May 30, 2023), Speaker/Honoraria (Terminated, May 30, 2023); Bayer: Consultant/Advisory Board (Terminated, May 31, 2022), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, May 31, 2022); Boehringer Ingelheim: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Merck: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, September 26, 2021); Novartis: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Novo Nordisk: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Servier: Consultant/Advisory Board (Terminated, October 30, 2022), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, October 30, 2022), Speaker/Honoraria (Terminated, October 30, 2022)